The Design Partner Program pairs your clinical-stage team with the HEOR Agent, built on A-HEMP — agentic AI that builds transparent, auditable cost-effectiveness and budget-impact models you can put in front of investors, partners, and payers.
Investors, BD partners, and payers ask what your asset is worth at Phase 2 — not at launch. The traditional answer is a six-figure HEOR consulting engagement: months of waiting for a black-box spreadsheet nobody outside the vendor can audit. Clinical-stage companies rarely have the budget, the timeline, or the internal HEOR expertise to do it any other way.
An HEOR Agent configured for your asset — cost-effectiveness (CEA/CUA) and budget-impact models with every input, equation, and source visible and traceable. First working model in days, not months.
Three months, human-in-the-loop. Your team runs the agent against performance metrics we agree upfront and inspects every assumption it makes.
License only if the agreed metrics are met — an annual license with a value-based performance component. If they aren't, you walk away.
An HEOR Agent configured for your asset: CEA/CUA and budget-impact models — every input, equation, and source visible and traceable.
Three months, human-in-the-loop. Your team runs the agent against performance metrics we agree upfront and inspects every assumption it makes.
License only if the agreed metrics are met — an annual license with a value-based performance component. If they aren't, you walk away.
A-HEMP builds the model itself — a glass box, not a black box. Every equation and citation is open to the investors, payers, and HTA reviewers who must trust it. What stays human: clinical judgment, comparator and pricing strategy, and every final decision.
Built by the person who used to build these models by hand.
Rapid Cognition's founder spent 25+ years leading health economic modeling for companies including Novartis, AstraZeneca, Shire, and Jazz Pharmaceuticals, with doctoral training spanning HEOR, AI/ML, and law and health policy. A-HEMP encodes that practice into a glass box — a model both sides of the table can inspect. Two design partners are already under MOU.
A small number of seats remain, reserved for clinical-stage teams heading into a raise, a Phase 2 readout, or BD discussions.